NASDAQ:PRANPrana Biotechnology Stock Price, Forecast & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Prana Biotechnology Limited Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.58 0.00 (0.00 %) (As of 06/5/2020 04:00 PM ET) Add Compare Share Today's Range$0.58Now: $0.58▼$0.6050-Day Range$0.95MA: $1.41▼$2.0652-Week Range$1.09Now: $0.58▼$2.91Volume137,709 shsAverage Volume130,956 shsMarket Capitalization$5.16 millionP/E RatioN/ADividend YieldN/ABeta1.05 ProfileFinancialsHeadlinesSEC FilingsSocial Media Prana Biotechnology Limited researches and develops therapeutic drugs for the treatment of Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidates include PBT434 that is in Phase I clinical trial for the treatment for Parkinson's disease and other movement disorders; and PBT2, which has completed four Phase I studies and a Phase IIa clinical trial for patients with Alzheimer's disease. It also completed the IMAGINE Phase II biomarker imaging trial in Alzheimer's disease; and a open label IMAGINE Extension study and the Reach2HD Phase IIa trial in Huntington disease. The company was founded in 1997 and is based in Melbourne, Australia.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Prana Biotechnology. Previous Next 2.0 Community Rank Outperform VotesPrana Biotechnology has received 188 “outperform” votes. (Add your “outperform” vote.)Underperform VotesPrana Biotechnology has received 277 “underperform” votes. (Add your “underperform” vote.)Community SentimentPrana Biotechnology has received 59.57% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Prana Biotechnology and other stocks. Vote “Outperform” if you believe PRAN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PRAN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldPrana Biotechnology does not currently pay a dividend.Dividend GrowthPrana Biotechnology does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Prana Biotechnology insiders have not sold or bought any company stock.Percentage Held by Insiders38.80% of the stock of Prana Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 3.63% of the stock of Prana Biotechnology is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Prana Biotechnology is -0.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Prana Biotechnology is -0.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPrana Biotechnology has a P/B Ratio of 0.41. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.73 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PRAN Previous Symbol CUSIPN/A CIK1131343 Webwww.pranabio.com Phone61-3-9349-4906Debt Debt-to-Equity RatioN/A Current Ratio4.37 Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$150,000.00 Price / Sales34.41 Cash FlowN/A Price / Cash FlowN/A Book Value$1.40 per share Price / Book0.41Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees14 Outstanding Shares8,900,000Market Cap$5.16 million Next Earnings DateN/A OptionableNot Optionable Receive PRAN News and Ratings via Email Sign-up to receive the latest news and ratings for PRAN and its competitors with MarketBeat's FREE daily newsletter. Prana Biotechnology (NASDAQ:PRAN) Frequently Asked Questions Has Prana Biotechnology been receiving favorable news coverage? News stories about PRAN stock have been trending neutral on Saturday, InfoTrie reports. The research group identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Prana Biotechnology earned a media sentiment score of 0.4 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the next few days. View the latest news aboutPrana Biotechnology. Who are some of Prana Biotechnology's key competitors? Some companies that are related to Prana Biotechnology include Synlogic (SYBX), Acasti Pharma (ACST), Alpine Immune Sciences (ALPN), Stealth BioTherapeutics (MITO), Enlivex Therapeutics (ENLV), DiaMedica Therapeutics (DMAC), CannTrust (CNTTF), Cassava Sciences (SAVA), Moleculin Biotech (MBRX), Capricor Therapeutics (CAPR), Vaccinex (VCNX), VERONA PHARMA P/S (VRNA), Aridis Pharmaceuticals (ARDS), Aclaris Therapeutics (ACRS) and Eyenovia (EYEN). View all competitors. What other stocks do shareholders of Prana Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some companies that other Prana Biotechnology investors own include NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), Novavax (NVAX), Catalyst Pharmaceuticals (CPRX), Intercept Pharmaceuticals (ICPT), Rigel Pharmaceuticals (RIGL), Arena Pharmaceuticals (ARNA), Conatus Pharmaceuticals (CNAT), Gilead Sciences (GILD) and GW Pharmaceuticals PLC- (GWPH). Who are Prana Biotechnology's key executives? Prana Biotechnology's management team includes the following people: Mr. Geoffrey Paul Kempler, Co-Founder, Exec. Chairman, CEO & MD (Age 64)Ms. Kathryn Andrews, Chief Financial Officer (Age 52)Dr. David A. Stamler, Chief Medical Officer, Sr. VP of Clinical Devel. and Member of R&D Advisory Board (Age 58)Prof. Rudolph Emile Tanzi, Chief Scientific Advisor and Member of R&D Advisory BoardDr. Steven D. Targum M.D., Chief Medical Advisor What is Prana Biotechnology's stock symbol? Prana Biotechnology trades on the NASDAQ under the ticker symbol "PRAN." What is Prana Biotechnology's stock price today? One share of PRAN stock can currently be purchased for approximately $0.58. How big of a company is Prana Biotechnology? Prana Biotechnology has a market capitalization of $5.16 million and generates $150,000.00 in revenue each year. The biotechnology company earns $-6,400,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. Prana Biotechnology employs 14 workers across the globe. What is Prana Biotechnology's official website? The official website for Prana Biotechnology is www.pranabio.com. How can I contact Prana Biotechnology? Prana Biotechnology's mailing address is Level 3 460 Bourke Street, Melbourne C3, 3000. The biotechnology company can be reached via phone at 61-3-9349-4906 or via email at [email protected] This page was last updated on 6/6/2020 by MarketBeat.com Staff
